Holden Stuart 4

What Happened

• Holden Stuart, a director of UroGen Pharma Ltd. (URGN), was granted a derivative award of 20,000 shares on 2026-06-22. The filing records the transaction as an award/grant (code A) at $0.00, indicating an equity award (stock option) rather than a cash purchase or sale. No immediate cash was exchanged in this transaction.

Key Details

• Transaction date: 2026-06-22; Form 4 filed: 2026-06-24 (appears timely within standard 2-business-day reporting window).
• Reported transaction: 20,000 shares (derivative stock option) granted at $0.00.
• Shares owned after transaction: not specified in the filing.
• Footnote: The shares underlying the stock option vest in equal quarterly installments over one year, subject to the director's continuous service under the 2017 Equity Incentive Plan.
• Transaction code: A (award/grant); derivative transaction (option) — not an exercise or sale.

Context

• This was a grant of an option-like award that vests over time; it does not represent an immediate sale or purchase of common stock and does not produce immediate proceeds. For retail investors, grants are routine compensation but are less directly informative than open-market purchases or sales because they reflect company compensation policy rather than an insider converting personal capital.